Spondyloarthropathies
Conference Coverage
Biologics improve axial spondyloarthritis patients’ work performance
Video
Observational data can’t answer question of inhibiting ankylosing spondylitis progression
AMSTERDAM –
Conference Coverage
TNF inhibitor may protect against axSpA sacroiliac joint progression
AMSTERDAM – In patients with axial spondyloarthritis, TNF inhibitor therapy is associated with slowing of sacroiliac joint radiographic...
Conference Coverage
Ankylosing spondylitis diagnosis linked to self-harm attempts
AMSTERDAM – Although a rare event, there is an increased risk of deliberate self-harm among those newly-diagnosed ankylosing spondylitis.
Conference Coverage
Axial SpA diagnostic strategies need not be sex-specific
AMSTERDAM – Imaging and HLA-B27 tests are key elements to identify early axial spondyloarthritis in both men and women.
Conference Coverage
EULAR scientific program highlights spectrum of translational research
Conference Coverage
Eye-opening findings cast spondyloarthritis in new light, expert says
New findings show that, in a surprisingly high number of patients, inflammatory back pain does not lead to axial SpA
Conference Coverage
Comorbid spondyloarthritis and fibromyalgia lower response to TNF inhibitors
LIVERPOOL, ENGLAND – Individuals with both axial spondyloarthritis and fibromyalgia respond to biologic therapy, but at a lower rate.
Conference Coverage
Physical therapy, exercise still relevant for ankylosing spondylitis
CAMBRIDGE, MASS.
Feature
Certolizumab pegol shows promise for nr-axSpA treatment
C-AXSPAND is the first year-long trial to show positive results vs. placebo in nonradiographic axial spondyloarthritis.
